Advertisement

Index by author

May 01, 1989; Volume 35,Issue 5

  1. Boelsterli, J J

    1. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model.
      M P Seiler, R Markstein, M D Walkinshaw and J J Boelsterli
      Molecular Pharmacology May 1989, 35 (5) 643-651;

  2. Bonaventura, B J

    1. A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes.
      J J Killackey, B J Bonaventura, A L Castelhano, R J Billedeau, W Farmer, L DeYoung, A Krantz and D H Pliura
      Molecular Pharmacology May 1989, 35 (5) 701-706;

  3. Bushfield, M

    1. Cation and structural requirements for P site-mediated inhibition of adenylate cyclase.
      R A Johnson, S M Yeung, D Stübner, M Bushfield and I Shoshani
      Molecular Pharmacology May 1989, 35 (5) 681-688;

  4. Castelhano, A L

    1. A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes.
      J J Killackey, B J Bonaventura, A L Castelhano, R J Billedeau, W Farmer, L DeYoung, A Krantz and D H Pliura
      Molecular Pharmacology May 1989, 35 (5) 701-706;

  5. Cook, J C

    1. Characterization of a specific binding protein for 2,3,7,8-tetrachlorodibenzo-p-dioxin in human thymic epithelial cells.
      J C Cook and W F Greenlee
      Molecular Pharmacology May 1989, 35 (5) 713-719;

  6. De Clercq, E

    1. 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine.
      J Balzarini, A Van Aerschot, R Pauwels, M Baba, D Schols, P Herdewijn and E De Clercq
      Molecular Pharmacology May 1989, 35 (5) 571-577;
    2. Differential inhibitory effects of several pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases.
      K Ono, H Nakane, P Herdewijn, J Balzarini and E De Clercq
      Molecular Pharmacology May 1989, 35 (5) 578-583;

  7. De Lean, A

    1. Distinct properties of atrial natriuretic factor receptor subpopulations in epithelial and fibroblast cell lines.
      J Féthière, S Meloche, T T Nguyen, H Ong and A De Lean
      Molecular Pharmacology May 1989, 35 (5) 584-592;

  8. Denny, W A

    1. Molecular modelling of DNA-antitumour drug intercalation interactions: correlation of structural and energetic features with biological properties for a series of phenylquinoline-8-carboxamide compounds.
      R McKenna, A J Beveridge, T C Jenkins, S Neidle and W A Denny
      Molecular Pharmacology May 1989, 35 (5) 720-728;

  9. Deyoung, L

    1. A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes.
      J J Killackey, B J Bonaventura, A L Castelhano, R J Billedeau, W Farmer, L DeYoung, A Krantz and D H Pliura
      Molecular Pharmacology May 1989, 35 (5) 701-706;

  10. Duman, R S

    1. A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase.
      D B Beitner, R S Duman and E J Nestler
      Molecular Pharmacology May 1989, 35 (5) 559-564;
« Previous (Pages : 1 2 3 4 5 6 7 ... 10) Next »
Back to top

In this issue

Advertisement